Did not receive study drug b n=2
Did not receive study drug n=4
Received study drug n=1,021 (safety analysis set) 
Notes:
a uptitration (from 16 mg/day to 24 mg/day) or downtitration (from 24 mg/day to 16 mg/day) of dose was allowed, based on tolerability and the investigator's judgment. Patients unable to tolerate a minimum of 16 mg/day dose were to discontinue treatment and were followed until the end of the maintenance and posttreatment period. The total number of patients included in the safety analysis set was n=2,045; b early study termination, per Data Safety monitoring Board recommendation, when the prespecified number of deaths was ascertained and a significant imbalance favoring galantamine was observed; c a one-time dose titration to 16 or 24 mg/day was allowed, based on the investigator's judgment and patient tolerability. Abbreviation: gal, galantamine.
